A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Heidi M. Ott(GlaxoSmithKline (United Kingdom)), Michael T. McCabe(GlaxoSmithKline (United States)), Roland S. Annan(GlaxoSmithKline (United Kingdom)), Dashyant Dhanak(Wilmington University), Alan P. Graves(GlaxoSmithKline (United States)), Edward Dul(GlaxoSmithKline (United States)), Steven D. Knight(GlaxoSmithKline (United States)), Wendy S. Halsey(GlaxoSmithKline (United States)), Sharad K. Verma(GlaxoSmithKline (United States)), Melissa B. Pappalardi(GlaxoSmithKline (United States)), Michael J. Huddleston(GlaxoSmithKline (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Ashley M. Hughes(GlaxoSmithKline (United States)), Ryan G. Kruger(Arysta LifeScience (France)), Caretha L. Creasy, Yong Jiang(GlaxoSmithKline (United States)), Arthur Groy(GlaxoSmithKline (United States)), Benjamin Schwartz, Yuchen Bai(The University of Melbourne)
Cited by 46
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848